Anita Verma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anita Verma has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Anil Dhawan
Paediatric Liver, GI and Nutrition Centre and Mowatlabs, King's College Hospital NHS Foundation Trust, London, UK
3 shared publications Giorgina Mieli‐Vergani
Paediatric Liver Centre King's College London School of Medicine at King's College Hospital London UK
2 shared publicationsJim J. Wade
Health Protection Agency, London, Region Laboratory, Department of Medical Microbiology, King's College Hospital, London, UK
2 shared publicationsA. Dhawan
Paediatric Liver Service
1 shared publicationAlastair J. Frcpch Baker
Paediatric Liver Centre King's College London School of Medicine at King's College Hospital London UK
1 shared publicationBeatrice Samaroo
Pediatric Liver Service, King's College Hospital, London, UK
1 shared publication
Latest Publications
- 11 May 2006
- Published by Wiley in Pediatric Transplantation
- Vol. 10 (5) , 536-548
Immunization issues before and after solid organ transplantation in children
Abstract: Solid‐organ transplant recipients are at risk from various infectious diseases, many of which can be prevented by immunizations that could reduce morbidity and mortality. However, it is not uncommon for children requiring transplantation to have received inadequate or no immunizations pre‐transplant. Every effort should be made to immunize transplant candidates early in the course of their disease according to recommended schedules prior to transplantation. It is also important to immunize their household contacts and healthcare workers. In this review, we summarize the major immunization issues for children undergoing transplantation, the data currently available on immunization safety and efficacy, and suggest immunization practices to reduce vaccine‐preventable disease. There is a real need for a standardized approach to the administration and evaluation of immunizations in this group of patients.
- 11 May 2006
- Published by Wiley in Pediatric Transplantation
- Vol. 10 (5) , 536-548
Immunization issues before and after solid organ transplantation in children
Abstract: Solid‐organ transplant recipients are at risk from various infectious diseases, many of which can be prevented by immunizations that could reduce morbidity and mortality. However, it is not uncommon for children requiring transplantation to have received inadequate or no immunizations pre‐transplant. Every effort should be made to immunize transplant candidates early in the course of their disease according to recommended schedules prior to transplantation. It is also important to immunize their household contacts and healthcare workers. In this review, we summarize the major immunization issues for children undergoing transplantation, the data currently available on immunization safety and efficacy, and suggest immunization practices to reduce vaccine‐preventable disease. There is a real need for a standardized approach to the administration and evaluation of immunizations in this group of patients.
- 1 March 2006
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 42 (3) , 282-286
Neonatal Herpes Simplex Virus Infection Presenting as Acute Liver Failure
Background: Acute liver failure (ALF) in neonates is rare but carries a high mortality without liver transplantation. Herpes simplex virus (HSV) is one of the microbes that more commonly causes ALF and is potentially treatable; hence, early diagnosis and treatment are important to avoid progression to liver failure.Patients and Results: We have analysed retrospectively the case notes of 11 patients with HSV‐induced ALF. A history of possible herpes infection was elicited in 5 parents, but HSV had not been suspected clinically. All patients were asymptomatic when discharged from postnatal units and were presented with nonspecific symptoms of poor feeding and lethargy within 2 weeks from birth. Seven of the 11 patients had HSV‐1 infection, 4 HSV‐2. Only 2 patients who received early treatment with intravenous acyclovir survived.Conclusions: HSV‐related ALF in the neonatal period carries high morbidity and mortality and needs a high index of suspicion so that life‐saving treatment can be started promptly. Both HSV‐1 and HSV‐2 can cause severe neonatal infection. It is important to recognise HSV infection in women of childbearing age and their sexual partners.
- 1 March 2006
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 42 (3) , 282-286
Neonatal Herpes Simplex Virus Infection Presenting as Acute Liver Failure
Background: Acute liver failure (ALF) in neonates is rare but carries a high mortality without liver transplantation. Herpes simplex virus (HSV) is one of the microbes that more commonly causes ALF and is potentially treatable; hence, early diagnosis and treatment are important to avoid progression to liver failure.Patients and Results: We have analysed retrospectively the case notes of 11 patients with HSV‐induced ALF. A history of possible herpes infection was elicited in 5 parents, but HSV had not been suspected clinically. All patients were asymptomatic when discharged from postnatal units and were presented with nonspecific symptoms of poor feeding and lethargy within 2 weeks from birth. Seven of the 11 patients had HSV‐1 infection, 4 HSV‐2. Only 2 patients who received early treatment with intravenous acyclovir survived.Conclusions: HSV‐related ALF in the neonatal period carries high morbidity and mortality and needs a high index of suspicion so that life‐saving treatment can be started promptly. Both HSV‐1 and HSV‐2 can cause severe neonatal infection. It is important to recognise HSV infection in women of childbearing age and their sexual partners.
- 9 March 2005
- Published by Wiley in Pediatric Transplantation
- Vol. 9 (2) , 220-225
Risk factors for fungal infection in paediatric liver transplant recipients
Abstract: Fungal infection (FI) is a major and potentially fatal complication in liver transplantation (LT). Published experience of FI in paediatric LT is limited. We therefore reviewed case records of 79 children, aged between 0.16 and 16 yr, who underwent LT between 1997 and 1998 to document the incidence of, and identify risk factors for, FI. Sixty‐eight pre‐, peri‐ and post‐LT variables were assessed in relation to FI by univariate and multivariate analyses. The major indications for LT were biliary atresia in 26 (33%) patients, fulminant hepatic failure in 16 (20%) and intrahepatic cholestasis in 11 (14%); eight patients required re‐LT. Thirty‐two (40.5%) children developed a FI within 1 yr of LT. The median time to FI was 42 days (range 1–342 days). Candida spp. caused 29 (90.7%) FIs; 21 (66%) of these were Candida albicans. Although FI was associated with increased mortality, most patients responded well to antifungal treatment. The variables independently associated with FI were pre‐LT fungal colonization and pyrexia and, post‐LT, bacterial infection, Epstein–Barr virus (EBV) infection and tacrolimus administration. Identifying risk factors for FI should contribute to the development of strategies for prophylaxis or preemptive therapy.
- 9 March 2005
- Published by Wiley in Pediatric Transplantation
- Vol. 9 (2) , 220-225
Risk factors for fungal infection in paediatric liver transplant recipients
Abstract: Fungal infection (FI) is a major and potentially fatal complication in liver transplantation (LT). Published experience of FI in paediatric LT is limited. We therefore reviewed case records of 79 children, aged between 0.16 and 16 yr, who underwent LT between 1997 and 1998 to document the incidence of, and identify risk factors for, FI. Sixty‐eight pre‐, peri‐ and post‐LT variables were assessed in relation to FI by univariate and multivariate analyses. The major indications for LT were biliary atresia in 26 (33%) patients, fulminant hepatic failure in 16 (20%) and intrahepatic cholestasis in 11 (14%); eight patients required re‐LT. Thirty‐two (40.5%) children developed a FI within 1 yr of LT. The median time to FI was 42 days (range 1–342 days). Candida spp. caused 29 (90.7%) FIs; 21 (66%) of these were Candida albicans. Although FI was associated with increased mortality, most patients responded well to antifungal treatment. The variables independently associated with FI were pre‐LT fungal colonization and pyrexia and, post‐LT, bacterial infection, Epstein–Barr virus (EBV) infection and tacrolimus administration. Identifying risk factors for FI should contribute to the development of strategies for prophylaxis or preemptive therapy.
- 1 June 2004
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 39 (Supplement) , S154
P0253 TARGETING HIGH RISK PATIENTS BY ANTIFUNGAL PROPHYLAXIS COULD PREVENT FUNGAL INFECTIONS AFTER LIVER TRANSPLANTATION IN CHILDREN
- 1 June 2004
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 39 (Supplement) , S154
P0253 TARGETING HIGH RISK PATIENTS BY ANTIFUNGAL PROPHYLAXIS COULD PREVENT FUNGAL INFECTIONS AFTER LIVER TRANSPLANTATION IN CHILDREN